Leverkusen, November 3, 2021 – With its comprehensive service range based around the exclusive synthesis of chemical agents and intermediates, Saltigo GmbH, a globally active subsidiary of the specialty chemicals company LANXESS, will be at CPhI Worldwide 2021, which will take place in Milan, Italy, from November 9 to 11. In addition to the agrochemical industry, customers of the Leverkusen-based specialist in exclusive synthesis include pharmaceutical companies and buyers of fine chemicals.

Focus on quality and delivery reliability

In relation to precursors and intermediates for the pharmaceutical industry in particular, where consistently high quality and high delivery reliability are key, Dr. Christoph Schaffrath, Head of Marketing and Sales at Saltigo, also sees good market opportunities for the future. “For a long time now, we have had an ongoing working relationship with numerous pharmaceutical companies who value our reliability and expertise,” he explains. One example of such a precursor is 1,2,4-(1H)-triazole, which is not produced exclusively and is used to make an antiviral active ingredient for oral application. 1,1’-carbonyldiimidazole is also widely used in coupling reactions in the process of making pharmaceutical active ingredients.

In the area of exclusive synthesis, it is the core competencies of Saltigo in particular, including hydrogenation in a pressurized environment and at high temperatures or catalyzed coupling reactions that attract a high level of interest from customers. Services such as process development, pilot testing, analytics and supporting customers through the registration of new substances complete the portfolio.

“Customer, technology and project need to be a good fit”

Synthesis steps under clean room conditions, at low temperatures, with complexreagents or in an inert gas atmosphere, as they are frequently encountered in theprocess for making active ingredients, also play an important role in other areas.This enables synergies to be exploited in respect of expertise as well as thetechnologies involved.

For example, a current field of activity at Saltigo in the fine chemistry sector iselectrolytes for lithium-ion batteries. “Thanks to our broad-based technologicalexpertise, we are extremely well positioned there too. Generally, the industry isless important than the customer, technology and project being a good fit,” saysDr. Michael Zobel, Chief Executive Officer of Saltigo GmbH, with conviction.Organic redox flow batteries could open up further prospects in the future assoon as the technology is market-ready. Redox-active electrolyte systems arerequired for this. “In this context, various substances are currently being testedfor their suitability, and we can well imagine supporting appropriatemanufacturers from scaling up the laboratory regulations up to production for themarket launch and beyond,” explains Schaffrath.

Detailed information about the comprehensive range of services offered bySaltigo in the area of exclusive synthesis can be found online athttps://saltigo.com/.